{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:59:06Z","timestamp":1791950346852,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T00:00:00Z","timestamp":1200009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tuberculosis (TB) caused by <jats:italic>Mycobacterium tuberculosis<\/jats:italic> continues to be one of the major public health problems in the world. The eventual control of this disease will require the development of a safe and effective vaccine. Bacille Calmette\u2010Guerin (BCG), the only vaccine against TB, is not perfect for its limited ability to protect against the adult form of TB. Some improvements of TB vaccines relied to strengthening the immunogenicity and\/or persistence of genetically modified recombinant BCG (rBCG) strain. Antigen 85B (Ag85B) and Mtb8.4 are importantly immunodominant antigens of <jats:italic>M. tuberculosis<\/jats:italic>, and both are very promising vaccine candidate molecules. MPT64<jats:sub>190\u2013198<\/jats:sub>, is presented to CD8<jats:sup>+<\/jats:sup> T cells during mycobacterial infections. In this study, we combined these above genes into one recombinant gene of <jats:italic>ag85B\u2013mpt64<\/jats:italic><jats:sub><jats:italic>190\u2013198<\/jats:italic><\/jats:sub><jats:italic>\u2013mtb8.4<\/jats:italic>. Then we constructed the new rBCG containing this united gene. This rBCG can induce an increased Th1\u2010type immune response in mice, characterized by an elevated level of interferon\u2010\u03b3 in antigen\u2010stimulated splenocyte culture and a strong IgG2a antibody response. Also, it can elicit longer immune responses than BCG. The results show that this rBCG is a promising candidate for further study.<\/jats:p>","DOI":"10.1111\/j.1365-3083.2007.02048.x","type":"journal-article","created":{"date-parts":[[2010,4,11]],"date-time":"2010-04-11T01:16:39Z","timestamp":1270948599000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of a new Recombinant BCG which Contains Mycobacterial Antigen ag85B\u2013mpt64<sub>190\u2013198<\/sub>\u2013mtb8.4 in C57\/BL6 Mice"],"prefix":"10.1111","volume":"67","author":[{"given":"Y. Q.","family":"Qie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. D.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1419"},{"key":"e_1_2_6_3_2","volume-title":"Global Tuberculosis Control: Surveillance, Planning, Financing","author":"WHO.","year":"2006"},{"key":"e_1_2_6_4_2","volume-title":"The World Health Report 2004: Changing History","author":"WHO","year":"2004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2003.08.011"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.1.126"},{"key":"e_1_2_6_7_2","first-page":"200","article-title":"Does the efficacy of BCG decline with time since vaccination?","volume":"2","author":"Sterne JA","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/24.5.1042"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92348-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2005.03.013"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.250480397"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.07.045"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1128\/iai.56.12.3310-3312.1988","article-title":"Induction of nonspecific acquired resistance and delayedtype hypersensitivity, but not specific acquired resistance, in mice inoculated with killed mycobacterial vaccines","volume":"56","author":"Orme I","year":"1988","journal-title":"Infect Immun"},{"key":"e_1_2_6_14_2","first-page":"3038","article-title":"Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30\u2010kilodalton major extracellular protein of Mycobacterium tuberculosis [published erratum appears in Infect Immun 1997;65(2):852]","volume":"64","author":"Harth G","year":"1996","journal-title":"Infect Immun"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5317.1420"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.10.6148-6150.2004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.5.2356"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.4.451"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2006.11.028"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2006.01812.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/334255a0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.6.3146-3154.2003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(03)00043-9"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.036"},{"key":"e_1_2_6_25_2","first-page":"27","article-title":"Increased IL\u20104 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease","volume":"18","author":"Ordway DJ","year":"2005","journal-title":"Acta Med Port"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.001045"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3083.2007.02048.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3083.2007.02048.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T16:59:10Z","timestamp":1696957150000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3083.2007.02048.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-3083.2007.02048.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3083.2007.02048.x","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,11]]},"assertion":[{"value":"2008-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}